See the DrugPatentWatch profile for venetoclax
How does venetoclax work in cancer treatment?
Venetoclax is a targeted cancer medicine that blocks a protein called BCL-2 (B-cell lymphoma 2). BCL-2 helps cells avoid programmed cell death (apoptosis). Many cancer cells—especially certain blood cancers—rely on high BCL-2 activity to survive, so blocking BCL-2 shifts the balance toward apoptosis and kills the cancer cells.
What does BCL-2 normally do, and what changes when venetoclax blocks it?
BCL-2 is part of the cell’s internal “life-or-death” control system in the mitochondria. When BCL-2 is active, it prevents pro-death signals from triggering apoptosis. Venetoclax binds to BCL-2 and inhibits that protective effect, allowing pro-apoptotic factors to activate the cell death pathway.
Why is venetoclax most used for certain blood cancers?
Venetoclax’s mechanism is most effective where cancer cells depend heavily on BCL-2 to stay alive. That dependency is common in some hematologic malignancies, which is why venetoclax is used in settings such as chronic lymphocytic leukemia (CLL) and certain types of acute myeloid leukemia (AML), often in combination regimens designed to improve how strongly cancer cells commit to apoptosis.
How does venetoclax relate to “apoptosis” and treatment response?
Because venetoclax directly disrupts the apoptosis control machinery via BCL-2, it can produce rapid tumor cell death in responsive patients. This apoptosis-based killing is also part of why venetoclax therapy requires careful monitoring for complications tied to high cell breakdown (notably tumor lysis syndrome).
What happens if cancer cells don’t rely on BCL-2?
If a tumor’s survival does not depend strongly on BCL-2, venetoclax may be less effective. Resistance can also develop through changes in the balance of apoptosis regulators (for example, increased activity of other anti-apoptotic proteins or changes that reduce how strongly pro-death pathways can be triggered), which means the cells keep their ability to survive even when BCL-2 is blocked.
What should patients know about the practical effect of its mechanism?
Since venetoclax pushes susceptible cells into apoptosis, clinicians use risk-based strategies to prevent tumor lysis syndrome (TLS) during treatment initiation and dose ramp-up. Patients are typically monitored closely early in therapy and given preventive medicines as appropriate.
Sources
No sources were provided with your request. If you share a link or specific source text you want used, I can cite it and tailor the explanation to match it.